Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Endo Dealt Patent Loss Amid Bankruptcy, Opioid Litigation (1)

Aug. 18, 2022, 2:40 PM

An Endo International Plc subsidiary failed to convince the Federal Circuit that a generic version of its bestselling blood-pressure drug infringed its patents, just days after Endo filed for bankruptcy to deal with debt and litigation stemming from its part in the US opioid epidemic.

Eagle Pharmaceuticals Inc.'s generic version of Vasostrict, which treats low blood pressure, doesn’t infringe Endo’s Par Pharmaceutical Inc.'s patents, the US Court of Appeals for the Federal Circuit ruled in a precedential opinion Thursday. The ruling affirmed the US District Court for the District of Delaware’s finding that Endo didn’t have enough evidence to prove ...